EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Galmed Pharmaceuticals Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 31, 2026
$2.85−0.00 (-0.00%)
Close on Oct 19, 2026
- Market cap
- $2.71M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Galmed Pharmaceuticals reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Galmed Pharmaceuticals's annual report. Trading prices and yields need FINRA TRACE data.